Barely Significant
← all excerpts

<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

JCO Precis Oncol · 2022 · PMC8984255 · PMID 35357905

Europe PMCDOI
1
hedged sentence
0.0530
closest p · 1.1× alpha
0.0530
boldest claim

The sentences

a near-significant trendP = .053so close (0.05 < p ≤ 0.1)
63 Although no significant differences were noted in the pCR rate between the buparlisib and placebo arms (32% v 40%), a near-significant trend was observed in the overall response rate (68.6% v 33%; P = .053) and a significant decrease was noted in Ki67 levels (75% v 26.7%; P = .021) favoring buparlisib in the subgroup of patients with HR+/HER2+ tumors. 63 Only eight of 50 enrolled subjects had PIK3CA mutations. 63 The study planned to recruit 256 patients but suspended recruitment early because of hepatotoxicity.

also in 290 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.